Array BioPharma Inc. (ARRY)

46.81
0.38 0.81
NASDAQ : Health Technology
Prev Close 46.44
Open 46.39
Day Low/High 46.39 / 46.90
52 Wk Low/High 12.56 / 29.81
Volume 11.68M
Avg Volume 2.77M
Exchange NASDAQ
Shares Outstanding 221.75M
Market Cap 6.56B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.

Array BioPharma To Present At The Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference

Array BioPharma To Present At The Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference

BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma To Present At The Jefferies 2019 Global Healthcare Conference

Array BioPharma To Present At The Jefferies 2019 Global Healthcare Conference

BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma Announces Presentation Of Updated Overall Survival From The Phase 3 COLUMBUS Trial Of BRAFTOVI MEKTOVI In Advanced BRAF-mutant Melanoma At 2019 ASCO Annual Meeting

Array BioPharma Announces Presentation Of Updated Overall Survival From The Phase 3 COLUMBUS Trial Of BRAFTOVI MEKTOVI In Advanced BRAF-mutant Melanoma At 2019 ASCO Annual Meeting

- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months -

Array BioPharma To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

Array BioPharma To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2019

Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2019

- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter -

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2019 On May 7, 2019

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2019 On May 7, 2019

BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Array BioPharma To Present At The 39th Annual Cowen Health Care Conference

Array BioPharma To Present At The 39th Annual Cowen Health Care Conference

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array BioPharma Inc.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Array BioPharma Surges as Loss Is Narrower Than Expected

Array BioPharma Surges as Loss Is Narrower Than Expected

The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.

Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2019

Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2019

- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% -

Interesting ARRY Put And Call Options For November 16th

Interesting ARRY Put And Call Options For November 16th

Investors in Array BioPharma Inc. saw new options begin trading this week, for the November 16th expiration.

First Week Of ARRY March 2019 Options Trading

First Week Of ARRY March 2019 Options Trading

Investors in Array BioPharma Inc. saw new options begin trading this week, for the March 2019 expiration.

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

Interesting ARRY Put And Call Options For December 21st

Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 21st expiration.

February Trade Ideas Rundown: How'd We Do?

February Trade Ideas Rundown: How'd We Do?

A fresh look at all 17 ideas: the winners, the losers and the still to be determined.

TheStreet Quant Rating: D (Sell)